检索结果-南通市图书馆

The real-world study of the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer in China

引用

胰腺病学杂志(英文) 2024年第1期7卷 1-9页

作者： Cui Jiujie Fu Qihan Chen Xiaobing Wang Yanling li Qi Wang Feng li Zhihua Dai Guanghai Wang Yusheng Zhang Hongmei liang Houjie Zhou Jun Yang liu Wang Fenghua Zheng Leizhen Chen Xiaofeng Gong Ping liu Jiang Yuan Ying Wang lin Cheng Yuejuan Zhang Jun Zhou Yuhong Guo Weijian Zhan Xianbao Zou Zhengyun li Da Zeng Shan li enxiao li Zhiwei Teng Zan Cao Dan Kan Jie Xiong Jianping Quan Ming Yao Jiayu Yang Haiyan Wang liwei Department of Medical Oncology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China Department of Medical Oncology The First Affiliated Hospital College of Medicine Zhejiang University Hangzhou China Department of Medical Oncology Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital Zhengzhou China Department of Medical Oncology Shanghai General Hospital Shanghai Jiao Tong University Shanghai China Department of Medical Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China Department of Medical Oncology Sun Yat-sen Medical Hospital Sun Yat-sen University Guangzhou China Medical Oncology Chinese PLA General Hospital Beijing China Department of Gastrointestinal Oncology Shanxi Provincial Cancer Hospital Affiliated to Shanxi Medical University Taiyuan China Department of Clinical Oncology Xijing Hospital Air Force Medical University Xi’an China Department of Oncology and Southwest Cancer Center Southwest Hospital Third Military Medical University (Army Military Medical University) Chongqing China Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing) Peking University Cancer Hospital &amp Institute Beijing China Cancer Center Department of Medical Oncology Zhejiang Provincial People’s Hospital People’s Hospital of Hangzhou Medical College Hangzhou China Department of Medical Oncology Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong China Oncology Department Xin Hua Hospital Affiliated to Shanghai JiaoTong University School of Medicine Shanghai China Department of Oncology the First Affiliated Hospital with Nanjing Medical University Nanjing China Department of Oncology The First Affiliated Hospital School of Medicine Shihezi University Shihezi China Department of Oncology People’s Hospital of Xinjia

Objective: Real-world diagnostic and treatment data for pancreatic cancer in China are lacking. As such, the present study investigated the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer (including locally advanced and metastatic disease) in the Hospital-based Advanced Pancreatic Cancer Cohort in China of the China Pancreas Data Center ***: A total of 5349 Chinese patients with advanced pancreatic cancer were identified from a database. The entire course of real-world pancreatic cancer management was ***: The proportion of patients with advanced pancreatic cancer was higher among males than females (62.4% vs 37.6%, respectively). Patients typically had a history of hypertension (30.8%), diabetes (21.6%), and cholangitis (20.2%). Abdominal pain (51.6%), abdominal distension (27.1%), jaundice (20.1%), and weight loss (16.3%) were the main symptoms observed in patients with advanced pancreatic cancer in this cohort. Serum carbohydrate antigen (CA)19-9 is one of the most common tumor markers. In the present study, 2562 patients underwent first-line therapy. The median progression-free survival (PFS) for patients undergoing first-line therapy was 4.1 months. The major options for first-line therapy included gemcitabine (GEM) plus S-1 (GS/X) (23.4%), nab-paclitaxel plus GEM (AG) (18.1%), oxaliplatin, irinotecan, and leucovorin-modulated fluorouracil (FOLFIRINOX; 11.9%), nab-paclitaxel plus S-1 (AS) (8.9%), and GEM combined with oxaliplatin/cisplatin (GEMOX/GP) (7.6%). The AS and GS/X regimens were associated with the highest PFS ***: This is the first study to report multicenter, real-world data regarding advanced pancreatic cancer in China. Results revealed that real-world treatment options differed from guideline recommendations, and PFS was shorter than that in previously reported data. Improving intelligent follow-up systems and standardizing diagnosis and treatment of pancreatic cancer is recomm

关键词： Advanced pancreatic cancer China Pancreas Data Center Chinese First-line regimens Real-world study

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib

引用

Chinese Journal of Cancer Research 2023年第5期35卷 526-535页

作者： Jianwei Zhang Haibin Zhu lin Shen Jie li Xiaoyan Zhang Chunmei Bai Zhiwei Zhou Xianrui Yu Zhiping li enxiao li Xianglin Yuan Wenhui Lou Yihebali Chi Nong Xu Yongmei Yin Yuxian Bai Tao Zhang Dianrong Xiu Jia Chen Shukui Qin Xiuwen Wang Yujie Yang Haoyun Shi Xian Luo Songhua Fan Weiguo Su Ming Lu Jianming Xu Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of Gastrointestinal OncologyPeking University Cancer Hospital&InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of RadiologyPeking University Cancer Hospital&InstituteBeijing 100142China State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers Beijing Key Laboratory of Carcinogenesis and Translational ResearchDepartment of Gastrointestinal OncologyPeking University Cancer Hospital&InstituteBeijing 100142China Department of Medical Oncology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100730China Department of Gastric Surgery State Key Laboratory of Oncology in South ChinaCollaborative Innovation Centre for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhou 510062China Department of Pancreatic and Hepatobiliary Surgery Fudan University Shanghai Cancer CenterShanghai 200032China Department of Abdominal Oncology West China HospitalSichuan UniversityChengdu 332001China Department of Medical Oncology the First Affiliated Hospital of Xi’an Jiaotong UniversityXi’an 710061China Department of Oncology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Department of General Surgery Zhongshan Hospital of Fudan UniversityShanghai 200032China Department of Medical Oncology National Cancer Center/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Medical Oncology the First Affiliated Hospital of Zhejiang UniversityHangzhou 310009China Department of Medical Oncology the First Affiliated Hospital of Nanjing Medical UniversityNanjing 210029China Department of Gastrointestinal Oncology Harbin Medical University Cancer HospitalHarbin 150081China Department of Oncology Union HospitalTongji Medical

Objective:Currently,pre-treatment prediction of patients with pancreatic neuroendocrine tumors with liver metastases(PNELM)receiving surufatinib treatment was *** objective was to examine the association between radiological characteristics and efficacy/***:We enrolled patients with liver metastases in the phase III,SANET-p trial(NCT02589821)and obtained contrast-enhanced computed tomography(CECT)*** and quantitative parameters including hepatic tumor margins,lesion volumes,enhancement pattern,localization types,and enhancement ratios were *** progression-free survival(PFS)and hazard ratio(HR)were calculated using Cox’s proportional hazard *** was analyzed by logistic-regression ***:Among 152 patients who had baseline CECT assessments and were included in this analysis,the surufatinib group showed statistically superior efficacy in terms of median PFS compared to placebo across various qualitative and quantitative *** the multivariable analysis of patients receiving surufatinib(N=100),those with higher arterial phase standardized enhancement ratio-peri-lesion(ASER-peri)exhibited longer PFS[HR=0.039;95%confidence interval(95%CI):0.003−0.483;P=0.012].Furthermore,patients with a high enhancement pattern experienced an improvement in the objective response ratio[31.3%vs.14.7%,odds ratio(OR)=3.488;95%CI:1.024−11.875;P=0.046],and well-defined tumor margins were associated with a higher disease control rate(DCR)(89.3%vs.68.2%,OR=4.535;95%CI:1.285−16.011;P=0.019)compared to poorlydefined ***:These pre-treatment radiological features,namely high ASER-peri,high enhancement pattern,and well-defined tumor margins,have the potential to serve as predictive markers of efficacy in patients with PNELM receiving surufatinib.

关键词： Neuroendocrine tumors liver metastases computed tomography surufatinib

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

胆道癌围手术期治疗进展

引用

现代肿瘤医学 2022年第22期30卷 4208-4213页

作者：王佳李恩孝樊扬威西安交通大学第一附属医院肿瘤内科陕西西安710061

胆道癌恶性程度高,预后极差,5年生存率不足5%。手术切除是目前胆道系统肿瘤唯一可能治愈的方法,但存在根治性切除率低、术后易复发等难题。围手术期治疗主要针对局部晚期恶性肿瘤,以放化疗为主要手段,能够提高手术切除率,防止疾病复发,... 详细信息

胆道癌恶性程度高,预后极差,5年生存率不足5%。手术切除是目前胆道系统肿瘤唯一可能治愈的方法,但存在根治性切除率低、术后易复发等难题。围手术期治疗主要针对局部晚期恶性肿瘤,以放化疗为主要手段,能够提高手术切除率,防止疾病复发,最终达到延长生存期的目的。目前已有多项胆道癌围手术期治疗模式的临床研究结果公布,为局部晚期胆道癌的综合治疗带来了新的选择。本文围绕新辅助治疗、辅助治疗和转化治疗三部分就局部晚期胆道癌的围手术期治疗热点及研究现状进行综述。

关键词：胆道癌围手术期治疗新辅助治疗辅助治疗转化治疗

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas

引用

Precision Clinical Medicine 2023年第4期6卷 226-238页

作者： Yina Jiang Yinying Wu liwen Zhang Yan Wang Guiping Xu Yuan Deng liang Han enxiao li Qingyong Ma Mian Xu Zheng Wu Zheng Wang Department of Pathology The First Affiliated Hospital of Xi’an Jiaotong UniversityXi’an 70061China Pancreatic disease treatment center Xi’an Jiaotong UniversityXi’an 70061China Department of Medical Oncology The First Affiliated Hospital of Xi’an Jiaotong UniversityXi’an 70061China OrigiMed Co.Ltd Shanghai 201114China Department of Radiology The First Affiliated Hospital of Xi’an Jiaotong UniversityXi’an 70061China Department of Hepatobiliary Surgery The First Affiliated Hospital of Xi’an Jiaotong UniversityXi’an 70061China

Adenosquamous carcinoma of the pancreas(ASCP)is a rare histological subtype of pancreatic cancer with a poor prognosis and a high metastasis ***,little is known about its genomic landscape and prognostic biomarkers.A total of 48 ASCP specimens and 98 pancreatic ductal adenocarcinoma(PDAC)tumour specimens were sequenced to explore the genomic landscape and prognostic *** homozygous deletion of the 9p21.3 region(including CDKN2A,CDKN2B,and MTAP)(9p21 loss)occurred in both ASCP and PDAC,and a higher frequency of 9p21 loss was observed in ASCP(12.5%vs 2.0%,P=0.022).Notably,9p21 loss was significantly associated with poor disease-free survival(DFS)in ASCP patients(mDFS(Median DFS)=4.17 vs 7.33 months,HR(Hazard Ratio)=3.70,P=0.009).The most common gene alterations in patients with ASCP were KRAS(96%),TP53(81%),CDKN2A(42%),SMAD4(21%),CDKN2B(13%),and FAT3(13%).The mutation rates of ACVR2A(6.25%vs 0%),FANCA(6.25%vs 0%),RBM10(6.25%vs 0%),and SPTA1(8.33%vs 1.02%)were significantly higher in ASCP than in *** conclusion,we have comprehensively described the genomic landscape of the largest cohort of ASCP patients to date and highlight that 9p21 loss may be a promising prognostic biomarker for ASCP,which provides a molecular basis for prognosis prediction and new therapeutic strategies for ASCP.

关键词： adenosquamous carcinoma of the pancreas genomic pattern 9p21 loss biomarker prognostic

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing,locally advanced or metastatic gastric or gastroesophageal junction cancer:a single-arm phase II study

引用

Cancer Communications 2021年第11期41卷 1173-1182页

作者： Zhi Peng Tianshu liu Jia Wei Airong Wang Yifu He liuzhong Yang Xizhi Zhang Nanfeng Fan Suxia Luo Zhen li Kangsheng Gu Jianwei Lu Jianming Xu Qingxia Fan Ruihua Xu liangming Zhang enxiao li Yuping Sun Guohua Yu Chunmei Bai Yong liu Jiangzheng Zeng Jieer Ying Xinjun liang Nong Xu Chao Gao Yongqian Shu Dong Ma Guanghai Dai Shengmian li Ting Deng Yuehong Cui Jianmin Fang Yi Ba lin Shen Department of Gastrointestinal Oncology Key Laboratory of Cancinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital&InstituteBeijing 100142P.R.China Department of Gastrointestinal Oncology Affiliated Zhongshan Hospital of Fudan UniversityShanghai 200032P.R.China Department of Oncology Nanjing Drum Tower Hospitalthe Affiliated Hospital of Nanjing University Medical SchoolNanjingJiangsu 210008P.R.China Department of Oncology Weihai Municipal HospitalWeihaiShandong 264299P.R.China Department of Oncology Anhui Provincial Cancer HospitalHefeiAnhui 230031P.R.China Department of Oncology The First Affiliated Hospital of Xinxiang Medical CollegeXinxiangHenan 453100P.R.China Department of Oncology Subei People’s HospitalYangzhouJiangsu 225009P.R.China Department of Abdominal Oncology Fujian Provincial Cancer HospitalFuzhouFujian 350014P.R.China Department of Gastrointestinal Oncology Henan Cancer HospitalZhengzhouHenan 450003P.R.China Department of Oncology Linyi Cancer HospitalLinyiShandong 276002P.R.China Department of Oncology The First Affiliated Hospital of Anhui Medical UniversityHefeiAnhui 230022P.R.China Department of Oncology Jiangsu Cancer HospitalNanjingJiangsu 210009P.R.China Department of Oncology The Fifth Medical Center of PLA General HospitalBeijing 100039P.R.China Department of Oncology The First Affiliated Hospital of ZhengzhouZhengzhouHenan 450099P.R.China Department of Oncology Sun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Department of Oncology Yantai Yuhuangding HospitalYantaiShandong 264099P.R.China Department of Oncology The First Affiliated Hospital of Xi’an Jiaotong UniversityXi’anShanxi 710061P.R.China Department of Oncology Jinan Central HospitalJinanShandong 250013P.R.China Department of Oncology Weifang People’s HospitalWeifangShandong 261041P.R.China Department of Oncology Peking Union Medical College HospitalBeijing 100005P.R.China Department of Oncology Xuzhou Central

Background:Current treatment options for human epidermal growth factor receptor 2(HER2)-overexpressing gastric cancer at third-line have shown limited clinical ***,there is no specific treatment for HER2 immunohistochemistry(IHC)2+and fluorescence in-situ hybridization-negative ***,we report the efficacy and safety of a novel anti-HER2 antibody RC48 for patients with HER2-overexpressing,advanced gastric or gastroesophageal junction ***:Patients with HER2-overexpressing(IHC 2+or 3+),locally advanced or metastatic gastric or gastroesophageal junction cancer who were under at least second-line therapy were eligible and received RC482.5 mg/kg alone every 2 *** primary endpoint was the objective response rate(ORR)assessed by an independent review *** endpoints included progressionfree survival(PFS),overall survival(OS),duration of response,time to progression,disease control rate,and ***:Of 179 patients screened,125 were eligible and received RC48 *** ORR was 24.8%(95%confidence interval[CI]:17.5%-33.3%).The median PFS and OS were 4.1 months(95%CI:3.7-4.9 months)and 7.9 months(95%CI:6.7-9.9 months),*** most frequently reported adverse events were decreased white blood cell count(53.6%),asthenia(53.6%),hair loss(53.6%),decreased neutrophil count(52.0%),anemia(49.6%),and increased aspartate aminotransferase level(43.2%).Serious adverse events(SAEs)occurred in 45(36.0%)patients,and RC48-related SAEs were mainly decreased neutrophil count(3.2%).Seven patients had adverse events that led to death were not ***:RC48 showed promising activity with manageable safety,suggesting potential application in patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy.

关键词： antibody-drug conjugate gastric cancer HER2-overexpressing phase II clinical trial RC48 third-line therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

阿帕替尼治疗晚期胰腺癌的疗效和安全性及疗效预测指标的探索

引用

现代肿瘤医学 2022年第22期30卷 4120-4124页

作者：董旭媛栾飞扬樊扬威吴胤瑛李恩孝董丹凤西安交通大学第一附属医院肿瘤内科陕西西安710061

目的:观察甲磺酸阿帕替尼治疗晚期胰腺癌的疗效与安全性,探索血清血管内皮生长因子(vascular endothelial growth factor,VEGF)和血管内皮生长因子受体-2(vascular endothelial growth factor receptor-2,VEGFR-2)水平与阿帕替尼疗效的关系。方法:本课题选择经病理确诊一线治疗进展后无法耐受或不愿接受二线化疗的晚期胰腺癌患者,经知情同意后给予阿帕替尼500 mg po qd治疗,2周期评估一次,主要观察指标为疾病控制率(disease control rate,DCR),次要观察指标为无进展生存期(progression-free survival,PFS)和不良反应;应用EliSA法检测治疗前患者血清VEGF和VEGFR-2水平;卡方检验分析血清VEGF和VEGFR-2水平与阿帕替尼疗效的关系。结果:本课题共入组24例一线治疗进展的晚期胰腺癌患者,可评估患者共23例。其中完全缓解(complete response,CR)0例、部分缓解(partial response,PR)1例(4.35%)、疾病稳定(stable disease,SD)8例(34.78%)、疾病进展(progressive disease,PD)14例(60.87%)。DCR为39.13%,中位PFS为2个月。阿帕替尼在治疗过程中出现的不良反应按照发生频率依次为乏力(91.30%)、高血压(52.17%)、口腔黏膜炎(52.17%)、蛋白尿(47.83%)、贫血(43.48%)、腹泻(21.74%)、呕吐(17.39%)、消化道出血(4.35%)、陈旧伤口裂开(4.35%)。在SD组和PD组中血清VEGF和VEGFR-2水平并没有明显差异。结论:对于一线治疗进展并且体力状况良好的晚期胰腺癌患者,阿帕替尼可以作为一个可选的治疗策略,血清VEGF和VEGFR-2水平不能预测阿帕替尼疗效。

关键词：胰腺癌阿帕替尼抗血管生成血管内皮生长因子血管内皮生长因子受体-2

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

重组人p53腺病毒注射液联合化疗治疗晚期宫颈癌的临床疗效观察

引用

实用癌症杂志 2019年第4期34卷 681-683页

作者：张丹李恩孝李曾西安交通大学附属三二0一医院 723000 西安交通大学医学院第一附属医院 710061

目的观察重组人p53腺病毒注射液联合顺铂与紫杉醇治疗晚期或复发宫颈癌的临床疗效。方法 80例晚期宫颈癌患者随机分为对照组和试验组,每组40例。对照组予紫杉醇联合顺铂化疗,试验组予重组人p53腺病毒注射液联合顺铂与紫杉醇治疗。观察2... 详细信息

目的观察重组人p53腺病毒注射液联合顺铂与紫杉醇治疗晚期或复发宫颈癌的临床疗效。方法 80例晚期宫颈癌患者随机分为对照组和试验组,每组40例。对照组予紫杉醇联合顺铂化疗,试验组予重组人p53腺病毒注射液联合顺铂与紫杉醇治疗。观察2组的客观缓解率(ORR)、疾病控制率(DCR)、无进展生存时间(PFS)和不良反应。结果试验组和对照组的ORR分别为55. 0%和32. 5%,DCR分别为75. 0%和60. 0%,差异均有统计学意义(P 0. 05)。结论重组人p53腺病毒注射液联合紫杉醇和顺铂可改善晚期及复发宫颈癌患者的临床疗效,且未增加不良反应,值得临床推广。

关键词：宫颈癌重组人p53腺病毒注射液紫杉醇顺铂

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

MDT模式在肿瘤学临床教学中的应用

引用

现代肿瘤医学 2019年第21期27卷 3869-3872页

作者：樊扬威李恩孝西安交通大学第一附属医院肿瘤内科

目的:在肿瘤学的临床教学中引入多学科综合治疗(multi-disciplinary treatment,MDT)模式,探讨其相对于传统教学模式的优势。方法:选取46名在肿瘤科实习的肿瘤学专业研究生、规范化培训学生或进修医生,随机分组后分别采取MDT教学模式和... 详细信息

目的:在肿瘤学的临床教学中引入多学科综合治疗(multi-disciplinary treatment,MDT)模式,探讨其相对于传统教学模式的优势。方法:选取46名在肿瘤科实习的肿瘤学专业研究生、规范化培训学生或进修医生,随机分组后分别采取MDT教学模式和传统教学模式进行培养,待实习结束后对两种教学模式的教学质量和教学满意度进行比较。结果:MDT教学组无论理论课考试成绩还是临床综合能力成绩均明显高于传统教学对照组(P<0.05);MDT教学组的学生在提高临床思维能力、激发自身学习兴趣、增强自主学习能力、增加交流与合作能力、提高表达能力和加深知识的理解和记忆等方面的教学满意度也显著高于传统教学组(P<0.05)。结论:在肿瘤学的临床教学中逐步推广MDT模式,可提高肿瘤学的教学质量和教学满意度。

关键词：肿瘤学临床教学多学科综合治疗教学质量教学满意度

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

同源异形盒基因D10启动子甲基化与胆管癌患者预后的关系

引用

肿瘤 2018年第5期38卷 469-475,512页

作者：杨海霞米建强梁军邵秋菊齐宇红常浩王启明李恩孝第四军医大学唐都医院放射治疗科陕西西安710038 第四军医大学肿瘤研究所陕西西安710038 河南科技大学第一附属医院病理科河南洛阳471003 西安交通大学第一附属医院肿瘤内科陕西西安710061

目的:研究同源异形盒基因D10(homeobox D10,HOXD 10)在人胆管癌组织中的启动子甲基化状态,并探讨HOXD 10基因启动子甲基化与胆管癌患者预后的关系。方法:采用甲基化特异性PCR法检测87例人胆管癌组织与30例癌旁组织中HOXD 10基因启动子... 详细信息

目的:研究同源异形盒基因D10(homeobox D10,HOXD 10)在人胆管癌组织中的启动子甲基化状态,并探讨HOXD 10基因启动子甲基化与胆管癌患者预后的关系。方法:采用甲基化特异性PCR法检测87例人胆管癌组织与30例癌旁组织中HOXD 10基因启动子的甲基化情况,并进一步采用重亚硫酸盐测序法检测HOXD 10基因启动子中27个胞嘧啶鸟嘌呤二核苷酸(cytosinephosphateguanosine,CpG)位点的甲基化程度。然后,应用Spearman相关检验分析HOXD 10基因启动子甲基化与其蛋白表达的相关性,用cutpoint生存分析和Kaplan-Meier法检验HOXD 10基因启动子区CpG位点甲基化数目与胆管癌患者预后的关系。结果:胆管癌组织中HOXD 10基因启动子甲基化率明显高于癌旁组织(P<0.05),而且癌旁组织中HOXD 10启动子区域的CpG位点数目少于胆管癌组织。HOXD10蛋白表达和HOXD 10基因启动子甲基化在胆管癌中呈显著负相关性(r=-0.82,P<0.000 1)。HOXD 10基因启动子区有7个CpG位点甲基化是胆管癌患者生存分析的最佳"截点"(P<0.001),CpG位点数目为0～6个的胆管癌患者生存时间明显长于CpG位点数目≥7个的患者(P<0.01)。结论:基因启动子甲基化与HOXD10蛋白的表达失活密切相关,HOXD 10基因启动子区存在≥7个CpG位点甲基化可作为胆管癌患者预后不良的预测指标之一。

关键词：胆管上皮癌 DNA甲基化预后同源异形盒基因D10

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

印甲薪对人乳腺癌细胞株MCF-7体外侵袭能力的作用研究

引用

现代肿瘤医学 2013年第5期21卷 995-998页

作者：李毅吴胤瑛李恩孝董丹凤西安交通大学医学院第一附属医院肿瘤内科陕西西安710061

目的:研究非甾体类抗炎药印甲薪对人乳腺癌细胞株MCF-7体外侵袭能力的影响。方法:通过细胞增殖抑制实验确定可应用于后续实验的印甲薪药物浓度,应用Transwell细胞体外侵袭实验研究印甲薪对MCF-7细胞移行及浸润能力的影响。结果:在安全... 详细信息

目的:研究非甾体类抗炎药印甲薪对人乳腺癌细胞株MCF-7体外侵袭能力的影响。方法:通过细胞增殖抑制实验确定可应用于后续实验的印甲薪药物浓度,应用Transwell细胞体外侵袭实验研究印甲薪对MCF-7细胞移行及浸润能力的影响。结果:在安全浓度范围内,随着印甲薪浓度的增加,MCF-7细胞的移行能力无明显变化,但浸润能力明显下降,与对照组相比有明显的统计学意义(P<0.05),并且浸润能力与印甲薪浓度呈负相关(r=-0.985)。结论:印甲薪可以明显抑制MCF-7细胞的体外侵袭能力,并且该抑制作用呈现浓度依赖性。

关键词：乳腺癌印甲薪移行浸润

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：